Endometrial Cancer Flashcards
What is the pathophysiology of endometrial cancer?
Stimulation of the endometrium by oestrogen without the protective effect of progesterone
What are risk factors for endometrial cancer?
- Obesity
- Diabetes mellitus
- Atypical endometrial hyperplasia
Menstrual factors:
- Early menarche
- Late menopause
- Nulliparity
Unopposed oestrogen:
- PCOS
- oestrogen only HRT
- Oestrogen secreting ovarian tumours
- Tamoxifen (E2 agonist at endometrium)
- Lynch syndrome/HNPCC
What is the most common type of endometrial cancer?
Endometrioid carcinoma
What histopathological findings are found in endometrial hyperplasia WITHOUT atypia?
Enlarged glands
Pleiomorphic
Mitosis
What histopathological findings are found in endometrial hyperplasia WITH atypia?
Abnormal glands:
- Dilated
- Budding/infolding of crowded glands
- Increased gland to stroma ratio
Atypia:
- Large, variable shape and size of nuclei
- Loss of polarity
- Increased nuclear to cytoplasmic ratio
- Hyperchromatism,
- Prominent nucleoli
- Abnormal mitotic figures
What were the findings of the Cochrane Review into Laparoscopy vs Laparotomy for Early Endometrial Cancer?
No difference in risk of
- death
- cancer recurrence
Laparoscopy associated with less blood loss and earlier discharge from hospital
In endometrial hyperplasia without atypia, what is the progression to endometrial cancer over 20 years?
<5%
Spontaneous resolution in up to 80%
With progesterone, resolution rates up to 96%
In endometrial hyperplasia with atypia, what is the risk of concomitant carcinoma?
22-43%
In patients undergoing hysterectomy
In endometrial hyperplasia with atypia, what is the risk of progression to endometrial cancer over 20 years?
30%
Spontaneous resolution in up to 30%
What is the standard management for endometrial hyperplasia with atypia?
Hysterectomy +/- BSO depending on menopausal status
What is the fertility sparing option for endometrial hyperplasia with atypia?
LNG IUS
Regression rates up to 86%
Timing of resampling: 6 months, then 12 months
? Role of removal of Mirena 1 month prior to enable accurate pathological assessment, remove pseudodecidualisation effect, progesterone effect
On completion of family, consideration of hysterectomy as risk of malignancy long-term is 11% with cessation of treatment
What % cases of endometrial cancer present premenopausally?
15%
What are two protective factors against endometrial cancer?
COCP
Smoking!
What are the three main lymphatic trunks of the corpus uteri?
Utero-ovarian (infundibulopelvic)
Parametrial
Presacral
They collectively drain into the hypogastric (also known as internal iliac), external iliac, common iliac, presacral and para-aortic nodes.
What are the most common metastatic sites for endometrial / uterine cancer?
Vagina
Ovaries
Lungs
What are the seven histopathological types of endometrial carcinomas?
- Endometrioid carcinoma
- Mucinous adenocarcinoma
- Serous adenocarcinoma
- Clear cell adenocarcinoma
- Undifferentiated carcinoma
- Neuroendocrine tumours
- Mixed carcinoma
What are the five histopathological types of mixed epithelial and mesenchymal uterine tumours?
- Adenomyoma
- Atypical polyploid adenomyoma
- Adenofibroma
- Adenosarcoma
- Carcinosarcoma
What are the two traditional classifications of endometrial cancers?
Type 1 tumours (80%):
- Grade 1 and 2 endometrioid carcinomas
- Risk factor: unopposed oestrogen exposure
- Arise from enodmetrial hyperplasia
- Affects younger, peri-menopausal women
Type 2 tumours (10-20%):
- Grade 3 endometrioid tumours
- Non-endometrioid tumours: serous, clear cell, mucinous, squamous, transitional cell, mesonephric and undifferentiated
- Arise from atrophic endometrium
- Less hormone sensitive
- Less differentiated, poorer prognosis.
- Affects older, post-menopausal women
Who is screening recommended for, in the context of endometrial cancer?
High risk groups ONLY, such as those with Lynch Syndrome
Pipelle and TV USS annually from the age of 35 until hysterectomy
Prophylactic TH+BSO should be discussed at the age of 40
(FIGO, 2018)
What was the key finding of the ASTEC study?
Removing pelvic nodes add staging information but no survival benefit was seen
What is the definition of endometrial hyperplasia?
Irregular proliferation of the endometrial glands with an increase in the gland to stroma ratio when compared with proliferative endometrium
(RCOG GTG)
Why have people advocated that progestogens be used to treat endometrial hyperplasia?
The progestogens modify the proliferative effects oestrogen on the endometrium
Discuss the management of endometrial hyperplasia WITHOUT atypia:
Identify and correct reversible risk factors:
- Weight loss
- Stop oestrogen only HRT or switch to combined HRT.
Observe alone OR commence progestogen treatment (indicated if failure to regress with observation alone or symptomatic with AUB):
- Mirena (1st line): at least 6 months duration; ideally up to 5 years.
- Continuous oral progestogen: at least 6 months duration,
Follow-up:
- Endometrial biopsy every 6 months.
- Need 2 x consecutive negative biopsies before discharging.
- Advise to seek review if abnormal bleeding occurs after completion of treatment.
- High risk women e.g. BMI >=35 or treatment with oral progestogens should have biopsy every 6 months; once 2 x consecutive negative biopsies obtained, increased biopsy interval to every year.
Indications for hysterectomy:
- Progression to atypia
- No regression after 12 months of treatment
- Relapse of hyperplasia after completion of treatment
- Persistence of bleedding
- Declines surveillance / non-compliance with medical treatment.
Choice of surgical approach:
- Laparoscopy preferred: shorter stay, less pain, quicker recovery
- If postmenopausal: offer total hysterectomy with BSO
- If premenopausal: offer total hysterectomy with BS
(RCOG, GTG)
What is the management for a patient with endometrial hyperplasia with atypia?
Surgery (first-line):
- Postmenopausal: total hysterectomy + BSO
- Premenopausal: total hysterectomy + BS; individualise choice of oophorectomy
Fertility sparing treatment OR not suitable for surgery:
- Exclude invasive endometrial cancer, co-existing ovarian cancer
- Refer to gynaecology oncology MDM for advice: management and surveillance.
- Medical treatment: Mirena (1st line) or oral progestogens (2nd line)
- Follow-up usually biopsy every 3/12 until 2 x consecutive negative biopsies then increase interval to every 6 to 12 months until hysterectomy performed.
- When fertility is no longer desired, offer hysterectomy.